D at Arrowhead, said, “Our Phase 1/2 study of ARO-HBV is designed to rapidly generate meaningful readouts on safety, tolerability and pharmacologic activity. The single-ascending dose and multiple-ascending dose phases are running nearly in parallel, as opposed to sequentially, which has allowed dose escalation and initiation of HBV patient dosing quickly.
I am new to this forum. I was wondering the tolerability of this new treatment of Hep C as I will probably be starting treatment with this new medicine. I have Hep C 1a too. I was wondering if I should prepare to take some time off work, I am a bus driver.
I worked the entire time I was on the other treatment and managed to survive but it was grueling as times unfortunately it didn't work, but I am optimistic with the new treatment. My concern is my awareness. I have to be sharp.
This study will evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) plus ribavirin (RBV) in treatment-naive adults with chronic genotype 3 hepatitis C virus (HCV) infection.
This study is currently recruiting participants Locations in Canada
First received: April 7, 2015
Last updated: NA
Last verified: April 2015
For more info
https://clinicaltrials.
Phase IIb Trial Will Further Assess Efficacy, Safety And Tolerability Of MK-7009 - For Patients With Chronic Hepatitis C
Results from an ongoing Phase IIa study showed that MK-7009, Merck Sharp and Dohme's (MSD) investigational oral hepatitis C virus (HCV) protease inhibitor, in combination therapy significantly improved rapid viral response, defined as viral suppression to undetectable levels within 28 days, compared to placebo in combination therapy in previously untreated (treatment-naïv
A study was performed to assess the efficacy and tolerability of rifaximin in the treatment of encephalopathy during cirrhosis of the liver. Fifty-five patients suffering from grade 1, 2 and 3 portosystemic encephalopathy, with a mean age of 58.9 years (range 30 to 86 years) were evaluated.
typically at our center we do not begin HCV treatment with interferon until the person has stage 2 scarring. you are coorect about the low tolerability of the current treatments as well as a small chance of rejection.
In the PHOENIX study, the Mayo Clinic team looked at the safety, tolerability, and safety of prophylactic peginterferon alfa-2a plus ribavirin therapy after liver transplantation in 115 patients randomized to treatment (55 patients) or observation (60 patients) 10 to 26 weeks after transplantation. The mean age in the prophylaxis group was 51.0 years (range, 35 to 68 years) and in the observation group was 53.5 years (range, 38 to 66 years).
The primary objectives of the Phase 1/1b study are to evaluate the safety and tolerability of TG1050 administered in single and multiple doses and to determine the dose and schedule of TG1050 administration for further development. Secondary objectives include evaluating the antiviral activity of and immune responses to TG1050. First data readout is expected in H2 2017.
To compare the efficacy, tolerability, and safety of IV methylprednisolone (IV MP) vs oral methylprednisolone (oMP) at equivalent high doses in patients with multiple sclerosis (MS) experiencing a recent relapse.
Methods:
Patients with a clinical relapse within the previous 2 weeks and at least 1 gadolinium (Gd)-enhancing lesion on a screening brain MRI scan were included.
GS-9620 checks a number of boxes for an interferon-better
Interferons for the treatment of chronic HepB and HepC is widely regarded as a mixed blessing. In light of its very poor tolerability, including flu-like symptoms and depression, patients often opt not to be potentially cured instead of suffering through a year or so of feeling just miserable.
These preliminary data demonstrate the tolerability and efficacy of REP 2139 and REP 2165 when used in combination with pegylated interferon alpha-2a and tenofovir disoproxil fumarate in patients with HBeAg-negative chronic HBV infection. NAP-mediated HBsAg clearance improves the efficacy of pegylated interferon alpha-2a in this patient population.
Particularly since the 10mg Bystolic tablets seemed to be the “sweet spot” in terms of tolerability. And the Bystolic worked very well for my BP. I am a 41 year old male.
To evaluate the efficacy and tolerability of an extended treatment protocol and to determine the predictors of sustained virological response (SVR) after liver transplantation (LT).
METHODS:
Between August 2005 and November 2008, patients with recurrent hepatitis C virus (HCV) after LT were selected for treatment if liver biopsy showed at least grade 2 inflammation and/or stage 2 fibrosis.
Truncation of therapy to 12-16 weeks should be considered only in patients who achieve rapid virologic response but experience tolerability issues. The AASLD guidelines note the standard of treatment for genotype 2 or 3 HCV infection is 24 weeks of peginterferon plus 800 mg/day of ribavirin.[19] Several studies have examined shortening of therapy in these patients.
Abrupt discontinuation of Pristiq can also cause paresthesia, which is described as electric shock sensations. Consult with your doctor to determine tolerability or if you may have to switch to another medication.
Recommended
